A SINGLE-CENTER OBSERVATIONAL STUDY OF CLINICAL OUTCOMES FOLLOWING TREATMENT OF LEIOMYOMA WITH COMBINATION THERAPY UTILIZING GNRH ANALOGS AND TRANSCERVICAL FIBROID ABLATION

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Leiomyoma
  • Age: Between 18 Year(s) - 50 Year(s)
  • Gender: Female
  • Other Inclusion Criteria:
    1. Seeking a uterus preserving fibroid treatment
    2. Presence of at least one large fibroid defined as fibroid diameter between 7-10 cm
    3. < 5 total fibroids with other fibroids <7cm in diameter in diameter at time of medical treatment initiation.
    4. Received medical treatment with GnRHa for a minimum of 3 months prior to TFA
    5. Received TFA between 1/2023 and 1/2024

You may not be eligible for this study if the following are true:

    1. Contraindicated for TFA: current pregnancy, active pelvic infection; Known or suspected gynecologic malignancy or premalignant disorders such as atypical endometrial hyperplasia, Presence of one or more intratubal implants for sterilization; presence of an intrauterine device (IUD)
    2. Contraindicated for GnRHa: extensive liver disease, breast cancer, thrombophilia, hypercholesterolemia, hypertriglyceridemia
    3. Anovulation or pregnant patients
    4. Unable to read and consent to English consent form



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.